Skip to main content
    B

    Bright Minds Biosciences Inc (DRUG)

    Official site

    HEALTHCARE • BIOTECHNOLOGY • NASDAQ

    $22.61
    -0.50 (-2.16%)

    Market Cap: $227.96M

    Last updated: Nov 17, 2026 at 11:03 AM ET

    Bright Minds Biosciences Inc (DRUG) Financials: Revenue, Profit and Cash Flow

    Updated Aug 14, 2026. Financial statements from company filings, amounts in CAD.

    Bright Minds Biosciences reported revenue of CAD 0 for the fiscal year ended Sep 30, 2025. That year, net income was CAD -12.23M, operating cash flow was CAD -8.69M and free cash flow was CAD -8.69M. The quarter ended Jun 30, 2026 had revenue of CAD 0 and net income of CAD -2.46M.

    Revenue and Margins

    The company reported no revenue in the fiscal year ended Sep 2025, with an operating loss of CAD 13.94M.

    Fiscal yearRevenueGrowthGross marginOperating marginNet margin
    Sep 20250N/AN/AN/AN/A
    Sep 20240N/AN/AN/AN/A
    Sep 20230N/AN/AN/AN/A
    Sep 20220N/AN/AN/AN/A
    Sep 20210N/AN/AN/AN/A
    Sep 20200N/AN/AN/AN/A
    Sep 2019N/AN/AN/AN/AN/A
    Annual, fiscal years ended Sep 2019 to Sep 2025

    Income Statement

    In the fiscal year ended Sep 2025, the net loss widened from the year before. In the quarter ended Jun 2026, the net loss narrowed from the same quarter a year earlier.

    Annual

    Line itemSep 2025Sep 2024Sep 2023Sep 2022Sep 2021Sep 2020Sep 2019
    Cost of revenue55.19KN/A72.45K6.04KN/AN/AN/A
    Gross profit-76.98KN/A-72.45K-6.04KN/AN/AN/A
    Research and development11.08M1.18M5.00M12.18M6.31M354.85K126.03K
    Operating income-13.94M-2.82M-7.39M-14.98M-8.76M-469.36K-236.15K
    Net income-12.23M-2.80M-7.37M-14.96M-8.52M-485.94K-236.15K
    EBITDA-12.15M-2.73M-7.30M-14.96M-8.76M-469.36K-78.72K
    Fiscal years ended Sep 2019 to Sep 2025

    Quarterly

    Line itemJun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023Sep 2023
    Gross profit-19.97K-20.13K-19.77K-12.21K-11.64KN/AN/AN/A-18.11K-18.11K-18.11K-18.11K
    Operating income-11.73M-15.57M-6.90M-5.66M-3.30M-3.35M-1.62M-791.31K234.74K-558.06K-1.70M-1.55M
    Net income-2.46M-10.63M-7.57M-4.09M-5.24M-2.95M49.61K-773.44K229.90K-574.14K-1.68M-1.53M
    Last 12 quarters

    Balance Sheet

    As of Sep 2025, cash and equivalents exceeded short-term debt of CAD 84.53K by 82.82M.

    Annual

    Line itemSep 2025Sep 2024Sep 2023Sep 2022Sep 2021Sep 2020Sep 2019
    Total assets84.42M6.10M6.88M12.09M20.04M880.22K163.97K
    Current assets84.31M5.99M6.81M11.95M20.04M878.22K79.99K
    Cash and equivalents82.91M5.72M6.75M11.63M19.76M799.93K79.99K
    Total liabilities2.38M568.26K280.86K1.54M638.57K150.92K36.71K
    Short-term debt84.53K79.38K73.55K67.93KN/AN/AN/A
    Shareholder equity82.04M5.54M6.60M10.54M19.40M729.29K127.26K
    Fiscal years ended Sep 2019 to Sep 2025

    Quarterly

    Line itemJun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023Sep 2023
    Total assets310.84M312.15M90.88M84.42M52.50M56.47M58.40M6.10M6.28M6.53M6.89M6.88M
    Total liabilities2.55M3.83M1.60M2.38M667.83K726.81K571.59K568.26K178.63K845.79K854.16K280.86K
    Cash and equivalents308.16M309.30M89.05M82.91M51.39M55.68M57.90M5.72M6.19M5.93M6.76M6.75M
    Shareholder equity308.30M308.32M89.28M82.04M51.83M55.74M57.83M5.54M6.10M5.69M6.03M6.60M
    Last 12 quarters

    Cash Flow

    Operating cash flow was negative in the fiscal year ended Sep 2025.

    Annual

    Line itemSep 2025Sep 2024Sep 2023Sep 2022Sep 2021Sep 2020Sep 2019
    Operating cash flow-8.69M-1.85M-7.02M-13.59M-7.32M-288.39K-42.01K
    Capital expenditures0050000
    Free cash flow-8.69M-1.85M-7.02M-13.59M-7.32M-288.39K-42.01K
    Financing cash flow85.57M810.57K2.19M5.20M26.06M1.01M122.00K
    Fiscal years ended Sep 2019 to Sep 2025

    Quarterly

    Line itemJun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023Sep 2023
    Operating cash flow-8.42MN/A-5.82M-1.27M-3.50M-2.43M-1.49M-463.17K240.16K-805.09K-822.09K-1.20M
    Free cash flow-8.42MN/A-5.82M-1.27MN/A-2.43M-1.49M-463.17K240.16K-805.09K-822.09K-1.20M
    Last 12 quarters

    Frequently Asked Questions About DRUG

    What is Bright Minds Biosciences' annual revenue?

    Bright Minds Biosciences reported revenue of CAD 0 for the fiscal year ended Sep 30, 2025.

    Is Bright Minds Biosciences profitable?

    No. Bright Minds Biosciences reported net income of CAD -12.23M for the fiscal year ended Sep 30, 2025.

    How much free cash flow does DRUG generate?

    For the fiscal year ended Sep 30, 2025, operating cash flow of CAD -8.69M minus capital expenditures of CAD 0 produced free cash flow of CAD -8.69M.

    How much debt does Bright Minds Biosciences have?

    The balance sheet dated Sep 30, 2025 reported short-term debt of CAD 84.53K and cash and equivalents of CAD 82.91M.